{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:02:37Z","timestamp":1789945357828,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-77065-3","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:03:39Z","timestamp":1787306619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["18 Month patency of acellular bioengineered regenerative conduit as coronary artery bypass"],"prefix":"10.1038","volume":"17","author":[{"given":"Abrielle","family":"Krouse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Soule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariah","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Benkofske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5536-6542","authenticated-orcid":false,"given":"Zeeshan H.","family":"Syedain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"77065_CR1","first-page":"e340","volume":"110","author":"KA Eagle","year":"2004","unstructured":"Eagle, K. A. et al. ACC\/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 110, e340\u2013e437 (2004).","journal-title":"Circulation"},{"key":"77065_CR2","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1056\/NEJMoa0804626","volume":"360","author":"PW Serruys","year":"2009","unstructured":"Serruys, P. W. et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N. Engl. J. Med. 360, 961\u2013972 (2009).","journal-title":"N. Engl. J. Med."},{"key":"77065_CR3","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(18)30423-9","volume":"391","author":"SJ Head","year":"2018","unstructured":"Head, S. J. et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet 391, 939\u2013948 (2018).","journal-title":"Lancet"},{"key":"77065_CR4","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1056\/NEJMoa1716026","volume":"378","author":"M Gaudino","year":"2018","unstructured":"Gaudino, M. et al. Radial-Artery or Saphenous-Vein Grafts in Coronary-Artery Bypass Surgery. N. Engl. J. Med. 378, 2069\u20132077 (2018).","journal-title":"N. Engl. J. Med."},{"key":"77065_CR5","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/jamacardio.2022.1437","volume":"7","author":"DJ Goldstein","year":"2022","unstructured":"Goldstein, D. J. et al. External support for saphenous vein grafts in coronary artery bypass surgery: a randomized clinical trial. JAMA Cardiol. 7, 808\u2013816 (2022).","journal-title":"JAMA Cardiol."},{"key":"77065_CR6","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1161\/CIRCULATIONAHA.117.027597","volume":"136","author":"M Gaudino","year":"2017","unstructured":"Gaudino, M. et al. Mechanisms, consequences, and prevention of coronary graft Failure. Circulation 136, 1749\u20131764 (2017).","journal-title":"Circulation"},{"key":"77065_CR7","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/SLA.0b013e318288c38d","volume":"257","author":"RE Harskamp","year":"2013","unstructured":"Harskamp, R. E., Lopes, R. D., Baisden, C. E., de Winter, R. J. & Alexander, J. H. Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions. Ann. Surg. 257, 824\u2013833 (2013).","journal-title":"Ann. Surg."},{"key":"77065_CR8","doi-asserted-by":"publisher","first-page":"68ra69","DOI":"10.1126\/scitranslmed.3001426","volume":"3","author":"SL Dahl","year":"2011","unstructured":"Dahl, S. L. et al. Readily available tissue-engineered vascular grafts. Sci. Transl. Med. 3, 68ra69 (2011).","journal-title":"Sci. Transl. Med."},{"key":"77065_CR9","doi-asserted-by":"publisher","unstructured":"Syedain, Z. H. et al. A completely biological \u201coff-the-shelf\u201d arteriovenous graft that recellularizes in baboons. Sci. Transl. Med. 9, https:\/\/doi.org\/10.1126\/scitranslmed.aan4209 (2017).","DOI":"10.1126\/scitranslmed.aan4209"},{"key":"77065_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/j.semvascsurg.2009.10.004","volume":"22","author":"MS Conte","year":"2009","unstructured":"Conte, M. S. Technical factors in lower-extremity vein bypass surgery: how can we improve outcomes? Semin. Vasc. Surg. 22, 227\u2013233 (2009).","journal-title":"Semin. Vasc. Surg."},{"key":"77065_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvssci.2022.11.001","volume":"4","author":"P Gutowski","year":"2023","unstructured":"Gutowski, P. et al. Six-year outcomes of a phase II study of human-tissue engineered blood vessels for peripheral arterial bypass. JVS Vasc. Sci. 4, 100092 (2023).","journal-title":"JVS Vasc. Sci."},{"key":"77065_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ejcts.2010.11.012","volume":"40","author":"T Athanasiou","year":"2011","unstructured":"Athanasiou, T. et al. Radial artery versus saphenous vein conduits for coronary artery bypass surgery: forty years of competition\u2013which conduit offers better patency? A systematic review and meta-analysis. Eur. J. Cardiothorac. Surg. 40, 208\u2013220 (2011).","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"77065_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/01.gim.0000196315.32179.82","volume":"1","author":"K Allen","year":"2005","unstructured":"Allen, K. et al. Endoscopic vascular harvest in coronary artery bypass grafting surgery: a consensus statement of the international society of minimally invasive cardiothoracic surgery (ISMICS) 2005. Innov. (Phila). 1, 51\u201360 (2005).","journal-title":"Innov. (Phila)."},{"key":"77065_CR14","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/S0140-6736(16)00557-2","volume":"387","author":"JH Lawson","year":"2016","unstructured":"Lawson, J. H. et al. Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials. Lancet 387, 2026\u20132034 (2016).","journal-title":"Lancet"},{"key":"77065_CR15","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1177\/11297298221147709","volume":"25","author":"A Ebner","year":"2024","unstructured":"Ebner, A. et al. First-in-human evaluation of a biological regenerative vascular conduit for hemodialysis access. J. Vasc. Access 25, 1271\u20131278 (2024).","journal-title":"J. Vasc. Access"},{"key":"77065_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100650","volume":"29","author":"O Sokolov","year":"2023","unstructured":"Sokolov, O. et al. Use of bioengineered human acellular vessels to treat traumatic injuries in the Ukraine-Russia conflict. Lancet Reg. Health Eur. 29, 100650 (2023).","journal-title":"Lancet Reg. Health Eur."},{"key":"77065_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jacbts.2022.06.021","volume":"8","author":"M Ono","year":"2023","unstructured":"Ono, M. et al. 1-Year patency of biorestorative polymeric coronary artery bypass grafts in an ovine model. JACC Basic Transl. Sci. 8, 19\u201334 (2023).","journal-title":"JACC Basic Transl. Sci."},{"key":"77065_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2025.101379","volume":"10","author":"AR Williams","year":"2025","unstructured":"Williams, A. R. et al. Acellular tissue engineered vessels as coronary artery bypass grafts. JACC Basic Transl. Sci. 10, 101379 (2025).","journal-title":"JACC Basic Transl. Sci."},{"key":"77065_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejvsvf.2022.01.003","volume":"54","author":"T Jakimowicz","year":"2022","unstructured":"Jakimowicz, T. et al. Five year outcomes in patients with end stage renal disease who received a bioengineered human acellular vessel for dialysis access. EJVES Vasc. Forum 54, 58\u201363 (2022).","journal-title":"EJVES Vasc. Forum"},{"key":"77065_CR20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000495355","volume":"49","author":"LC Bylsma","year":"2019","unstructured":"Bylsma, L. C. et al. Clinical outcomes of arteriovenous access in incident hemodialysis patients with medicare coverage, 2012-2014. Am. J. Nephrol. 49, 156\u2013164 (2019).","journal-title":"Am. J. Nephrol."},{"key":"77065_CR21","doi-asserted-by":"publisher","first-page":"101465","DOI":"10.1016\/j.jacbts.2025.101465","volume":"11","author":"MY Emmert","year":"2026","unstructured":"Emmert, M. Y., Generali, M., Hoerstrup, S. P. & Zilla, P. Model choice and interpretation in coronary tissue engineering: still more questions than answers? JACC Basic Transl. Sci. 11, 101465 (2026).","journal-title":"JACC Basic Transl. Sci."},{"key":"77065_CR22","doi-asserted-by":"crossref","unstructured":"Ebner, A., Soule, M., Krouse, A., McMahon, M. & Syedain, Z. Clinical evaluation of completely biological engineered vessel for coronary artery bypass. JACC Case Rep. 31, 107487 (2026).","DOI":"10.1016\/j.jaccas.2026.107487"},{"key":"77065_CR23","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1089\/ten.tea.2013.0550","volume":"20","author":"ZH Syedain","year":"2014","unstructured":"Syedain, Z. H., Meier, L. A., Lahti, M. T., Johnson, S. L. & Tranquillo, R. T. Implantation of completely biological engineered grafts following decellularization into the sheep femoral artery. Tissue Eng. Part A 20, 1726\u20131734 (2014).","journal-title":"Tissue Eng. Part A"},{"key":"77065_CR24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/1746-6148-9-192","volume":"9","author":"A Weigand","year":"2013","unstructured":"Weigand, A. et al. New aspects on efficient anticoagulation and antiplatelet strategies in sheep. BMC Vet. Res. 9, 192 (2013).","journal-title":"BMC Vet. Res."},{"key":"77065_CR25","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.biomaterials.2008.11.011","volume":"30","author":"G Konig","year":"2009","unstructured":"Konig, G. et al. Mechanical properties of completely autologous human tissue engineered blood vessels compared to human saphenous vein and mammary artery. Biomaterials 30, 1542\u20131550 (2009).","journal-title":"Biomaterials"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77065-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77065-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77065-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:32:22Z","timestamp":1789943542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77065-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77065"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77065-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Matthew Soule is a consultant for Vascudyne. Dr. Zeeshan Syedain, Mariah McMahon, Abrielle Krouse, and Jake Benkofske are shareholders and employees of Vascudyne. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9991"}}